The prevalence and clinical significances of KRAS, GNAS, and RNF43 mutations in patients with pancreatic intraductal papillary mucinous neoplasm (IPMN) remain elusive. The gene discussed is KRAS; the disease is pancreatic intraductal papillary-mucinous neoplasm.